New Brunswick, NJ-based Johnson & Johnson announced that its fourth quarter revenues rose 8.5% with its medical devices and diagnostics division seeing an increase just slightly below its corporate sales rise.

The entire company’s revenues jumped to $13.7 billion while the medical devices and diagnostics division rose 7% to $5.2 billion.

The device unit registered an increase despite disappointing sales from J&J’s Cypher drug-coated heart stent, which has been linked along with similar products to fatal blood clots. Cypher’s worldwide sales fell 15% to $580 million and U.S. sales dropped 18% to $280 million, J&J said.

Revenue from the Cordis unit that makes Cypher fell 4% worldwide to $961 million. Cypher sales in the quarter were $280 million in the U.S. and $580 million worldwide. According to the company, Cypher has 48% of the market globally.

Sales from other devices rose. Revenue from DePuy, which makes orthopedic products for reconstructing damaged or diseased joints, climbed 8% to $1.1 billion.

Revenues for the next quarter are expected to be impacted by the Nov. 16 acquisition of Conor Medsystems to gain marketing rights to CoStar, a drug-coated stent that may reduce the risk of blood clots. CoStar, sold in other countries, is not approved for use in the U.S. J&J can terminate the purchase if additional test results make U.S. approval unlikely.